## Dolores Jaraquemada

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8774118/publications.pdf

Version: 2024-02-01

70 papers 2,849 citations

201674 27 h-index 52 g-index

72 all docs 72 docs citations

times ranked

72

3022 citing authors

#	Article	IF	CITATIONS
1	Isolation of HLA-DR-naturally presented peptides identifies T-cell epitopes for rheumatoid arthritis. Annals of the Rheumatic Diseases, 2022, , annrheumdis-2021-220371.	0.9	5
2	Global Proteomic and Methylome Analysis in Human Induced Pluripotent Stem Cells Reveals Overexpression of a Human TLR3 Affecting Proper Innate Immune Response Signaling. Stem Cells, 2019, 37, 476-488.	3.2	7
3	Central Tolerance Mechanisms to TSHR in Graves' Disease: Contributions to Understand the Genetic Association. Hormone and Metabolic Research, 2018, 50, 863-870.	1.5	13
4	Analysis of the HLA-DR peptidome from human dendritic cells reveals high affinity repertoires and nonconventional pathways of peptide generation. Journal of Leukocyte Biology, 2017, 101, 15-27.	3.3	34
5	Interleukin-13 Pathway Alterations Impair Invariant Natural Killer T-Cell–Mediated Regulation of Effector T Cells in Type 1 Diabetes. Diabetes, 2016, 65, 2356-2366.	0.6	9
6	Central T cell tolerance: Identification of tissue-restricted autoantigens in the thymus HLA-DR peptidome. Journal of Autoimmunity, 2015, 60, 12-19.	6.5	27
7	Divergent paths for the selection of immunodominant epitopes from distinct antigenic sources. Nature Communications, 2014, 5, 5369.	12.8	62
8	The Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell Transplantation. Journal of Clinical Medicine, 2014, 3, 373-387.	2.4	8
9	Peptides presented by HLA class I molecules in the human thymus. Journal of Proteomics, 2013, 94, 23-36.	2.4	14
10	The Repertoires of Peptides Presented by MHC-II in the Thymus and in Peripheral Tissue: A Clue for Autoimmunity?. Frontiers in Immunology, 2013, 4, 442.	4.8	22
11	Low frequency of GITR+ T cells in ex vivo and in vitro expanded Treg cells from type 1 diabetic patients. International Immunology, 2013, 25, 563-574.	4.0	32
12	Composition of the HLAâ€DRâ€associated human thymus peptidome. European Journal of Immunology, 2013, 43, 2273-2282.	2.9	38
13	Unraveling features of the natural MHC class II peptidome of skin-migrated dendritic cells. International Immunology, 2012, 24, 59-69.	4.0	3
14	Informe de la 2.a Reunión de la Sociedad de InmunologÃa de la Comunidad Autónoma de Madrid (SICAM). Inmunologia (Barcelona, Spain: 1987), 2011, 30, 68-74.	0.1	0
15	The peptide-binding motif of HLA-DR8 shares important structural features with other type 1 diabetes-associated alleles. Genes and Immunity, 2011, 12, 504-512.	4.1	19
16	TCR Bias of In Vivo Expanded T Cells in Pancreatic Islets and Spleen at the Onset in Human Type 1 Diabetes. Journal of Immunology, 2011, 186, 3787-3797.	0.8	38
17	Women advancing science. European Journal of Immunology, 2010, 40, 589-592.	2.9	2
18	Increased Apoptosis after Autoimmune Regulator Expression in Epithelial Cells Revealed by a Combined Quantitative Proteomics Approach. Journal of Proteome Research, 2010, 9, 2600-2609.	3.7	21

#	Article	IF	CITATIONS
19	The rheumatoid arthritis–associated allele HLA–DR10 ( <i>DRB1*1001</i> ) shares part of its repertoire with HLA–DR1 ( <i>DRB1*0101</i> ) and HLA–DR4 ( <i>DRB*0401</i> ). Arthritis and Rheumatism, 2008, 58, 1630-1639.	6.7	34
20	$\hat{l}^{3}\hat{l}f$ Lymphocytes in endocrine autoimmunity: evidence of expansion in Graves' disease but not in type 1 diabetes. Clinical and Experimental Immunology, 2008, 92, 288-295.	2.6	27
21	Influx of recent thymic emigrants into autoimmune thyroid disease glands in humans. Clinical and Experimental Immunology, 2008, 153, 338-350.	2.6	27
22	Chapter 6 Peptides Presented In Vivo by HLA-DR in Thyroid Autoimmunity. Advances in Immunology, 2008, 99, 165-209.	2.2	13
23	Thyroglobulin Peptides Associate In Vivo to HLA-DR in Autoimmune Thyroid Glands. Journal of Immunology, 2008, 181, 795-807.	0.8	48
24	Analysis of the HLA class I associated peptide repertoire in a hepatocellular carcinoma cell line reveals tumor-specific peptides as putative targets for immunotherapy. Proteomics - Clinical Applications, 2007, 1, 286-298.	1.6	7
25	Effect of glatiramer acetate (Copaxone $\hat{A}^{\otimes}$ ) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: A longitudinal study. Neuroscience Letters, 2006, 406, 270-275.	2.1	53
26	Human intestinal $\hat{l}\pm\hat{l}^2$ IEL clones in celiac disease show reduced IL-10 synthesis and enhanced IL-2 production. Cellular Immunology, 2006, 244, 1-9.	3.0	10
27	CD1a and CD1c Activate Intrathyroidal T Cells during Graves' Disease and Hashimoto's Thyroiditis. Journal of Immunology, 2005, 174, 3773-3780.	0.8	54
28	Evolution of brain-derived neurotrophic factor levels after autologous hematopietic stem cell transplantation in multiple sclerosis. Neuroscience Letters, 2005, 380, 122-126.	2.1	14
29	Dissection of the HLA-DR4 Peptide Repertoire in Endocrine Epithelial Cells: Strong Influence of Invariant Chain and HLA-DM Expression on the Nature of Ligands. Journal of Immunology, 2004, 173, 1085-1093.	0.8	46
30	HLA-DRB1 alleles and HLA-DRB1 shared epitopes are markers for juvenile rheumatoid arthritis subgroups in Colombian mestizos. Human Immunology, 2004, 65, 359-365.	2.4	23
31	Functional analysis of HLA-DP polymorphism: a crucial role for DPbeta residues 9, 11, 35, 55, 56, 69 and 84-87 in T cell allorecognition and peptide binding. International Immunology, 2003, 15, 565-576.	4.0	93
32	Polimorfismo de los alelos de los antÃgenos de leucocitos humanos HLA-DRB1 y su asociación con la artritis reumatoidea juvenil en una muestra de niños mestizos colombianos Biomedica, 2003, 23, 254.	0.7	6
33	HLA-DR4 Molecules in Neuroendocrine Epithelial Cells Associate to a Heterogeneous Repertoire of Cytoplasmic and Surface Self Peptides. Journal of Immunology, 2002, 169, 5052-5060.	0.8	31
34	CD4+ bias in T cells cloned from a CML patient with active graft versus leukemia effect. Cytotherapy, 2002, 4, 353-363.	0.7	11
35	T-cell reactivity to glutamic acid decarboxylase in stiff-man syndrome and cerebellar ataxia associated with polyendocrine autoimmunity. Clinical and Experimental Immunology, 2002, 129, 471-478.	2.6	34
36	Thyroid Autoimmune Disease. American Journal of Pathology, 2001, 159, 861-873.	3.8	261

#	Article	IF	CITATIONS
37	HLA-DM and invariant chain are expressed by thyroid follicular cells, enabling the expression of compact DR molecules. International Immunology, 1999, 11, 269-277.	4.0	19
38	HLA-DM can partially replace the invariant chain for HLA-DR transport and surface expression in transfected endocrine epithelial cells. Tissue Antigens, 1999, 53, 447-458.	1.0	8
39	Th1 Predominance and Perforin Expression in Minor Salivary Glands from Patients with Primary Sjögren's Syndrome. Journal of Autoimmunity, 1999, 13, 155-162.	6.5	67
40	Lack of HLA-G soluble isoforms in Graves-Basedow thyrocytes and complete cDNA sequence of the HLA-G*01012 allele. International Journal of Immunogenetics, 1998, 25, 311-315.	1.2	15
41	Hyperexpression of transporter in antigen processing-1 (TAP-1) in thyroid glands affected by autoimmunity: a contributory factor to the breach of tolerance to thyroid antigens?. Clinical and Experimental Immunology, 1997, 109, 98-106.	2.6	14
42	Singleâ€eell analysis of intrathyroidal lymphocytes shows differential cytokine expression in Hashimoto's and Graves' disease. European Journal of Immunology, 1997, 27, 3290-3302.	2.9	109
43	Cloning of Candidate Autoantigen Carboxypeptidase H from a Human Islet Library: Sequence Identity with Human Brain CPH. Journal of Autoimmunity, 1996, 9, 525-528.	6.5	4
44	Different requirements of ICAM-1/LFA-1 adhesion in allorecognition and self-restricted antigen recognition by class II-specific T cell clones. European Journal of Immunology, 1994, 24, 947-951.	2.9	5
45	Processing pathways for presentation of cytosolic antigen to MHC class II-restricted T cells. Nature, 1992, 357, 702-704.	27.8	200
46	Efficient cDNA expression vectors for stable and transient expression of HLA-DR in transfected fibroblast and lymphoid cells. Human Immunology, 1991, 31, 229-235.	2.4	128
47	On the relative immunogenicity of DR alloantigens: T cell recognition of HLA-DR2a and HLA-DR2b. Human Immunology, 1991, 30, 215-221.	2.4	12
48	A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis Journal of Experimental Medicine, 1991, 173, 19-24.	8.5	287
49	Structural requirements for pairing of alpha and beta chains in HLA-DR and HLA-DP molecules Journal of Experimental Medicine, 1990, 171, 615-628.	8.5	36
50	An endogenous processing pathway in vaccinia virus-infected cells for presentation of cytoplasmic antigens to class II-restricted T cells Journal of Experimental Medicine, 1990, 172, 947-954.	8.5	197
51	Recombinant CD4-Pseudomonas Exotoxin Hybrid Protein Displays HIV-Specific Cytotoxicity without Affecting MHC Class II-Dependent Functions. AIDS Research and Human Retroviruses, 1990, 6, 795-804.	1.1	29
52	HLAâ€D region heterogeneity in a Nigerian population. Tissue Antigens, 1989, 33, 445-456.	1.0	18
53	Clonal heterogeneity of HLA-B27 cellular allo-recognition. Delineation of immunodominant sites. European Journal of Immunology, 1988, 18, 203-209.	2.9	10
54	Modulation on immunogenicity by HLA-B27 subtype polymorphism. European Journal of Immunology, 1988, 18, 1945-1950.	2.9	10

#	Article	IF	CITATIONS
55	Alloreactive cytolytic T cell clones with dual recognition of HLA-B27 and HLA-DR2 antigens. Selective involvement of CD8 in their class I-directed cytotoxicity Journal of Experimental Medicine, 1987, 165, 428-443.	8.5	51
56	HLA-Dw specificity assignments are independent of HLA-DQ, HLA-DR, and other class II specificities and define a biologically important segregant series which strongly activates a functionally distinct T cell subset. Human Immunology, 1986, 16, 259-270.	2.4	15
57	HLA-DR4 as a predictor of outcome three years after onset of rheumatoid arthritis. Rheumatology International, 1986, 6, 233-235.	3.0	26
58	HLA and rheumatoid arthritis: a combined analysis of 440 British patients Annals of the Rheumatic Diseases, 1986, 45, 627-636.	0.9	102
59	Genetic and functional relationship of the HLA-DR and HLA-DQ antigens. Immunogenetics, 1985, 21, 97-101.	2.4	26
60	HLAâ€B15 heterogeneity in different populations. Tissue Antigens, 1985, 25, 33-37.	1.0	3
61	Different functions and associations of HLAâ€DR and HLAâ€DQ(DC) antigens shown by serological, cellular and DNA assays. Tissue Antigens, 1985, 25, 130-141.	1.0	20
62	HLA polymorphisms in Nigerians. Tissue Antigens, 1985, 25, 142-155.	1.0	45
63	HLA polymorphisms in a Shanghai Chinese population. Tissue Antigens, 1984, 23, 23-32.	1.0	14
64	Serological analogue of HLAâ€Ðw9. Tissue Antigens, 1982, 19, 233-237.	1.0	4
65	Sources of variance in the double normalized value: an evaluation of its reproducibility as a measure on HLA-D locus identity. Tissue Antigens, 1981, 18, 141-153.	1.0	2
66	MHC Specified Lymphocyte Activating and Suppressor Activating Determinants in Human Mixed Lymphocyte Reactions. Scandinavian Journal of Immunology, 1981, 14, 655-667.	2.7	14
67	Intra HLA–D Region Recombinant Maps HLA–DR between HLA–B and HLA–D. Tissue Antigens, 1981, 17, 43-56.	1.0	29
68	Type 1 diabetes and the HLA-D locus. Diabetologia, 1980, 18, 41-43.	6.3	66
69	"la-like―antigens on human T cells. European Journal of Immunology, 1979, 9, 356-362.	2.9	113
70	Response to: Correspondence on "HLA-DR †naturally' presented peptides: you will find what you have pulsed with†by Maggi <i>et al</i> . Annals of the Rheumatic Diseases, 0, , annrheumdis-2022-222758.	0.9	0